ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

• https://x.com/RHEUMarampa/status/2062506356192538724/photo/1

COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

• https://x.com/AurelieRheumo/status/2062491277191438681/photo/1

Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach), Non peptide based (can be given anytime). Know about s/e and contraindications. May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar. #EULAR2026 @RheumNow https://t.co/KNudYN29PT

• https://x.com/bella_mehta/status/2062486603633684696/photo/1
• https://x.com/bella_mehta/status/2062486603633684696/photo/1

#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh

• https://x.com/DrMiniDey/status/2062485261921964380/photo/1

#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0

• https://x.com/DrMiniDey/status/2062483752043872563/photo/1

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

• https://x.com/DrMiniDey/status/2062474451246318046/photo/1

What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC

• https://x.com/Janetbirdope/status/2062462900006953077/photo/1
• https://x.com/Janetbirdope/status/2062462900006953077/photo/1

Brand new #MOA in #Rx of #skin #lupus! #Litifilimab - acts on #dendritic cells ⬇️decreases #chemokines & #cytokines +RCT in #cutaneous features of lupus N=93 2:1 randomized #liti v #pbo Rapid onset <4wks HIgh #CLASI response #EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU

• https://x.com/Janetbirdope/status/2062459007638389179/photo/1
• https://x.com/Janetbirdope/status/2062459007638389179/photo/1

#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

• https://x.com/Yuz6Yusof/status/2062458622936760812/photo/1

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

• https://x.com/RHEUMarampa/status/2062458264655134775/photo/1

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1
• https://x.com/AurelieRheumo/status/2062454356176171351/photo/1

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

• https://x.com/Yuz6Yusof/status/2062469410732790078/photo/1

Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026

#OP0219 at #EULAR2026: Real-world ASTER data suggest DORIS remission & LLDAS are achievable with anifrolumab in routine practice, assoc w ⬇️risk of organ damage accrual. Over 12m, 43% attained DORIS remission & 74% LLDAS. Low serious adverse event rates reported. @RheumNow

#EULAR2026 OP0216 With the advances in biologics/cell-based therapies in #SLE, we need to define “severe refractory.” Data-driven analysis from 13 nations suggested: SLEDAI≥6 + PGA>1 + mild-moderate or severe flare (MMSf) + GC≥10 +IS. Need validation study before use @RheumNow https://t.co/K2dMSQUIgB

• https://x.com/Yuz6Yusof/status/2062436505902096486/photo/1